AChE inhibitors as eserine, tacrine, donepezil, rivastigmine, and galanthamine are the only drugs currently approved for the treatment of AD; however, these drugs are known to have limitations for clinical use due to their short-half-lives and/or unfavor- able side-effects (Sung et al. 2002).